Brucellosis is a worldwide zoonosis causing important economic loss and a public 
LPS tests (Ducrotoy, Conde-Álvarez, Blasco, & Moriyón, 2016) . Vaccination of exclusively young replacements minimizes this interference (particularly when Rev1 is applied by the conjunctival route) but does not fully solve the problem of differentiating vaccinated animals (Fensterbank, Pardon, & Marly, 1982 , 1985 .
Several approaches to generate vaccines or strategies to allow differentiation between infected and vaccinated animals (DIVA) have been studied (Blasco, Moreno, & Moriyón, 2016; Yang et al., 2013) .
Since most infected animals react against Brucella cell envelope antigens, efforts have been focused on the removal of immunogenic relevant proteins such as outer membrane and binding proteins (Cloeckaert et al., 2004; Grilló et al., 2009; Guilloteau et al., 2006; Jacques et al., 2007) or O-polysaccharide epitopes (Godfroid et al., 2000; González et al., 2008) . Unfortunately, these approaches entail eventual inconveniences that limit the practical usefulness of the tagging deletion such as: (a) an excessive attenuation and/or loss of vaccine efficacy (Barrio et al., 2009; González et al., 2008) ; (b) the lack of specificity of the associated tests to detect specific antibodies against the deleted antigen in infected animals ); and (c) a potential positive selective advantage for virulent bacteria against the attenuated vaccine strain (Moreno, 2014 ).
An alternative approach has been the inclusion of antigens xenogenic for Brucella, such as Trypanosoma cruzi immunogenic proteins (Comerci, Pollevick, Vigliocco, Frasch, & Ugalde, 1998; Pollevick, Affranchino, Frasch, & Sanchez, 1991) or the Green Fluorescent Protein (GFP) from the Aequorea victoria jellyfish (Chacón-Díaz et al., 2011) in combination with associated diagnostic tests. Both approaches were performed by encoding the xenogenic antigens through a non-integrative plasmid, limiting the usefulness of these vaccines in field conditions.
We have developed a Rev1 vaccine strain carrying the gfp gene stably inserted in the chromosome (Rev1::gfp) that maintains the biological properties of the reference vaccine and is readily identified by ultraviolet (UV) illumination and PCR-GFP multiplex. In this work, several immunization strategies were conducted in mice and then in lambs to induce anti-GFP antibodies identified by an associated indirect ELISA-GFP, thus, allowing the identification of vaccinated animals.
| MATERIAL AND METHODS

| Bacterial strains, growth conditions, inocula preparation, plasmids used and DNA manipulations
The bacterial strains and plasmids used in this study are listed in Table 1 . Bacteria were routinely grown in Blood Agar Base n°2 (BAB; Oxoid), Luria Bertani Broth (LB; Pronadisa) or Trypticase Soy Broth (TSB; Pronadisa) either plain or supplemented with selected antibiotics (all from Sigma-Aldrich Química) such as kanamycin 50 μg/ml (Km 50 ) or 35 μg/ml (Km 35 ), ampicillin 100 μg/ml (Amp 100 ), polymyxin B 1.5 μg/ml (PxB 1.5 ), gentamicin 15 μg/ml (Gm 15 ), streptomycin 2.5 μg/ml (Str 2.5 ) or penicillin G 5 μg/ml (P 5 ). Bacterial strains were stored at −20°C in 10% skimmed milk supplemented with 3% sterile lactose (Applichem Panreac).
Brucella suspensions were prepared in sterile Phosphate Buffered Saline (PBS; pH 7.2) by spectrophotometry (SmartSpec Plus Spectrophotometer, BioRad) and exact doses were determined retrospectively, as described previously . Also, inocula of purified recombinant GFP (see below) were prepared in PBS, sterilized through 0.22 μm filters (Millipore ® ) and further quantified by Bradford (BioRad).
Escherichia coli S17 (λpir) strains carrying specific plasmids for mini-Tn7 based integration assays, that is, pUC18T-mini-Tn7-gfp-Gm (Choi & Schweizer, 2006 ) and pUC18R6KT-mini-Tn7-Km (Llobet, March, Giménez, & Bengoechea, 2009) 
| Construction of pUC18R6KT-mini-Tn7-gfp-Km
The plasmid pUC18T-mini-Tn7-gfp-Gm was used to generate the cloning vector pCR2.1-gfp carrying both the gfp gene and the E.
coli rrnB P1 ribosomal promoter (Table 1) by: (a) gfp amplification from the pUC18T-mini-Tn7-gfp-Gm by PCR using the primers rrnBP1-F and Gfp_f-R2 (Table 2) ; (b) extraction of a DNA fragment (ATP Gel/PCR Extraction Kit, ATP biotech Inc.) from the gel agarose electrophoresis; and (c) insertion of the DNA fragment into the pCR2.1-TOPO (TOPO TA Cloning kit, Thermo Fisher Scientific). Then, the pUC18R6KT-mini-Tn7-gfp-Km (Table 1) was constructed by digestion of the pCR2.1-gfp with EcoRI (Takara) for extracting the rrnB P1-gfp fragment and further insertion into pUC18R6KT-mini-Tn7-Km by using a T4 ligase (Invitrogen). The resulting pUC18R6KT-mini-Tn7-gfp-Km was checked by sequencing (Secugen) and, then, transformed in E. coli S17 (λpir) by thermal shocking.
| Construction and genetic characterization of
Rev1::gfp
The chromosomal insertion of the gfp in B. melitensis Rev1 was performed by the mini-Tn7 directed mutagenesis method, using the suicide vector pUC18R6KT-mini-Tn7-gfp-Km. This method allows the gfp insertion into the attTn7 non-codifying site usually located 25 nucleotides downstream of the glucosamine-fructose-6-phosphate aminotransferase (glmS) gene, which is highly conserved amongst bacteria and present in Brucella (Choi & Kim, 2009; Choi & Schweizer, 2006; Choi et al., 2005) . Thus, a preliminary study in silico was performed in order to assess the exact chromosomal localization and the percentage of homology of glmS in B. melitensis with respect to other brucellae. For this, the Blast-Tools of the National Center for Biotechnology Information (NCBI) database (NCBI, 2018) for Brucella spp. and sequencing (Secugen) of the glmS downstream attTn7 site were performed in Rev1 by using the GlmS_B and RecG primers (Table 2) . Thereafter, the protocol of mini-Tn7-gfp insertion between glmS and recG genes described by Choi (Choi & Schweizer, 2006) was adapted to B. melitensis Rev1 strain (Figure 1a ). Briefly, a tetraparental conjugation was achieved by mixing 0.5 ml of the Rev1 receptor strain previously grown in TSB (37°C, overnight) and 0.2 ml of each E.
coli S17 (λpir)-pUC18R6KT-mini-Tn7-gfp-Km, E. coli SM10 (λpir)-pTNS2 and E. coli HB101-pRK2013, all previously grown (37°C, overnight) in LB supplemented with the corresponding antibiotic of selection (Table 1 ). The bacterial mix was washed twice with 1.5 ml of MgSO 4 10 mM, dissolved in 30 μl of MgSO 4 and dropwise cultured (37°C, 6 hr) in BAB. Finally, bacteria were harvested in PBS, decimally diluted and cultured (37°C, 5-6 days) in a BABPxB 1.5 -Km 50 plate to select the desired Rev1::gfp transformed clones.
The proper insertion and orientation of the mini-Tn7-gfp were assessed in ten Rev1::gfp transconjugant clones by using four individual PCR with the following pairs of primers: (a) GlmS_B and Tn7-R; (b) Tn7-L and RecG; (c) Gfp-F and Gfp_R; and (d) GlmS_B and RecG, as described in Table 2 . As represented in Figure 1a, and 20 μg/ml, and safranin 100 μg/ml; Sigma) and antibiotics (i.e., penicillin and streptomycin) markers were assessed by standard protocols (Alton, Jones, Angus, & Verger, 1988) . 
T A B L E 1 Bacterial strains and plasmids used in this work
Brucella melitensis
| In vitro growth
Bacterial growth curves were determined in vitro by both spectrophotometry and bacterial Colony Forming Units (CFU) counts.
Briefly, TSB suspensions containing 1 × 10 2 CFU/ml were incubated (37°C, under shaking) for 7 days, and tested at selected intervals for assessing the Optical Density at 600 nm (OD 600 nm ) and the CFU/ml on BAB plates. The mean ± SD (n = 3) values of individual OD 600 nm readings and log 10 CFU/ml were calculated and compared statistically by a one-way ANOVA followed by the Fisher's Protected Least Significant Differences (PLSD) test.
| Stability of GFP tagging in Rev1::gfp
The stability of the gfp insertion and GFP expression in Rev1::gfp was assessed after: (a) 20 subcultures in BAB plates; (b) storage of cultures in plates at 4°C for 3 months; (c) two consecutive passages in mice (Grilló, Blasco, Gorvel, Moriyón, & Moreno, 2012); each spleen culture in mice virulence experiments. DNA from a representative number of individual colonies from each subculture or spleen culture were extracted and checked by a one-step multiplex PCR-GFP using a mix of GlmS_B, Tn7-R, RecG, Gfp-F and Gfp-R primers (Table 2) (Table 1) lysates were used as negative and positive controls, respectively, and a gradient of recombinant GFP containing 6, 3, 1.5 or 0.75 μg/ml of GFP was used as protein ladder. The prestained Protein Marker VI (AppliChem) was used as molecular marker of 10-245 kDa.
| Recombinant GFP production, characterization and study of stability
Recombinant GFP labelled with glutathione-S-transferase (GST) was obtained and purified by affinity chromatography (GST GraviTrap Primers used in PCR-GFP multiplex for Rev1::gfp identification ( Figure 1 ). In Rev1 and other conventional Brucella, GlmS_B and RecG primers amplify a 328 bp band.
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Tn7R gfp Tn7L (Table 1) . After purification, GFP was excised from the fusion protein using an enzymatic treatment (37°C, 24 hr) with 100 IU/mg thrombin (GE Healthcare ® ). The purity and antigenicity of both GFP isoforms were determined by SDS-PAGE followed by Coomassie staining and WB anti-GFP, as described above. The stability to temperature was assessed by incubating GFP-GST and GFP suspensions (100 μl aliquots) at 4, 37, 44 and 60°C, for 9 weeks. Moreover, the stability to UV radiation was assessed by submitting the GFP suspensions placed in 96-well plates (60 μl/well; Maxisorp, Nunc ® ) to an UV intensity of 11.34 J, administered in 18 pulses (i.e., equivalent to 90 hr of natural outdoor exposure) in a microwave irradiator (Stratalinker). In both experiments, the GFP stability was determined by both direct visualization of fluorescence under UV illumination and WB antigenicity procedures, as described above.
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| ELISA-GFP validation
The presence of anti-GFP antibodies was determined by an indirect ELISA-GFP in both mice and sheep studies (see below). For this, 96 well plates (Maxisorp, Nunc ® ) were coated with 1 μg/well of GFP in 0.1 M carbonate buffer, blocked with skimmed milk (2% in PBSTween 0.1%) and tested with 1/100 serum dilutions in PBS.
Reactions were revealed using the corresponding peroxidase conjugate (i.e., anti-IgG H+L rabbit anti-mouse at 1/5,000 in PBS or Protein G diluted at 1/4,000 in PBS, for mice and sheep, respectively; both conjugates were from Thermo Scientific) and ABTS ( and the cut-off selected was that resulting in 100% Se and Sp for discriminating both GFP-positive and GFP-negative populations.
| Mice studies
Eight-week old BALB/c female mice (Charles River) were accommodated for 1 week in the P3 facilities (registration code ES/31-2016-000002-CR-SU-US) of the IdAB (Navarra, Spain). Animals were kept in cages with water and food ad libitum under biosafety containment conditions. Animal handling and procedures were in accordance with the current Spanish (RD 53/2013) and European (Directive 14/86/ 609/EEC) legislations, and following the FELASA (Rehbinder et al., 2000) and ARRIVE (Kilkenny, Browne, Cuthill, Emerson, & Altman, 2010) international recommendations.
General procedures in mice were performed as described previously (Grilló et al., , 2012 . Briefly, bacterial inocula were prepared in sterile PBS just before administration, so that each mouse received the inoculation dose in 0.1 ml, either intraperitoneally (IP) or subcutaneously (SC). The exact doses of Brucella were determined retrospectively as described elsewhere . Blood samples were taken by retrorbital plexus puncture and the serum samples were obtained by centrifugation (4,000 rpm, 10 min) and kept at −20°C until use. At the end of each experiment, mice were slaughtered by cervical dislocation and the spleens were removed and processed individually, in sterile conditions, for determining the mean ± SD (n = 5) of individual log 10 CFU/spleen, at each selected point-time (Grilló et al., 2012) . Statistical comparisons of means were performed by one-way ANOVA and the Fisher's PLSD tests.
| Virulence
Groups of 25 mice were inoculated IP with 1 × 10 6 CFU/mouse of Rev1::gfp or Rev1 reference strain (control) and the number of log 10 CFU/spleen was determined at 1, 3, 6, 9 and 12 weeks after inoculation, as described elsewhere (Grilló et al., 2012) .
| Vaccine efficacy
The protection conferred by Rev1::gfp against a virulent challenge in mice was assessed following standard procedures (Grilló et al., 2012; OIE, 2016 (Table 1) and, 2 weeks after challenge, the log 10 CFU/spleen of the virulent strain was determined by plating in BAB-Gm 15 .
| Obtaining GFP-hyperimmunized sera
BALB/c mice (n = 5) were inoculated SC three consecutive times, (at day 0, week 4 and week 6) with 0.1 ml of a suspension containing 20 μg of recombinant GFP mixed 1:1 (vol:vol) with Incomplete ZABALZA-BARANGUÁ ET AL.
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Freund's Adjuvant (IFA, Sigma-Aldrich, Spain). Pre-immunization sera were obtained and used as GFP-negative controls of the ELISA-GFP plates (see Section 2.6.).
| Serological response after vaccination
Two consecutive experiments were performed:
In the first experiment we assessed the anti-GFP response 
| Obtaining GFP-hyperimmunized sera
Lambs (n = 6) were inoculated SC three consecutive times, (at day 0, week 4 and week 6) with 0.5 ml of a suspension containing 62.5 μg of recombinant GFP mixed 1:1 (vol:vol) with IFA. Pre-immunization sera were obtained and used as GFP-negative controls of the ELISA-GFP plates.
| Serological response after vaccination
Based on the results obtained in mice, two sequential experiments were designed to study the serological responses after vaccination in lambs.
The first experiment was conducted to assess (a) the ability of Rev1::gfp to generate anti-GFP antibodies; (b) the enhancement of anti-GFP response induced when Rev1::gfp was combined with recombinant GFP; and (c) the effect in the anti-GFP response when the combination Rev1::gfp+GFP was complemented with a booster with recombinant GFP in either PBS or IFA adjuvant. For this, lambs were vaccinated SC either (n = 6) with 1 ml of a suspension containing 1-2 × 10 9 CFU of Rev1::gfp prepared as described (Barrio et al., 2009 ) or (n = 8) with 2 ml of a suspension containing 1 ml of Rev1::
gfp and 1 ml of a sterile suspension with 100 μg recombinant GFP. 
| RESULTS
| Rev1::gfp carried the mini-Tn7-gfp inserted between glmS and recG genes of B. melitensis Rev1
The in silico analysis showed only one glmS gene in brucellae that is highly conserved amongst various species (99% homology; Supporting information Table S1 ). Rev1 glmS was not annotated in NCBI database. DNA sequencing confirmed the presence of attTn7 site and the Tn7-gfp insertion at 25 nucleotides downstream of the glmS gene in Rev1::gfp, as reported for other bacterial species (Choi & Schweizer, 2006) . The ten Rev1::gfp clones checked by different PCR showed the expected genotype (Table 2, Figure 1 ).
| Rev1::gfp kept the phenotype of the
B. melitensis Rev1 reference strain and expressed GFP
Rev1::gfp showed the phenotypic characteristics of its isogenic Rev1 parental strain (Grilló, Bosseray, & Blasco, 2000) , 
| Recombinant GFP was immunogenic and highly stable to temperature and UV radiation
The stability of recombinant GFP and GFP-GST used for animal immunizations and for ELISA-GFP was assessed under stressing conditions. A total loss of fluorescence was observed after 1 week of incubation at 60°C, and it was accompanied by a significant loss of antigenicity (Supporting information Figure S1 ). Full antigenicity and a slight loss of fluorescence were observed after a 9-week incubation period at 37 and 44°C. Storage at 4°C for at least 5 months did not affect the fluorescence or antigenicity of GFP. Both, GFP and GFP-GST were stable after 90 hr UV radiation (Supporting information Figure S1 ).
| Anti-GFP antibody response in mice
The optimal ELISA-GFP cut-off (allowing a proper differentiation of GFP-positive and GFP-negative sera) was ≥30.33% OD 405 nm and culling strategy, has allowed the eradication of small ruminant brucellosis in some countries . However, Rev1
induces an anti S-LPS response in vaccinated animals that makes eradication difficult. Thus, the generation of anti-Brucella DIVA vaccines that could facilitate implementing eradication programs in small ruminants has been a recurrent topic of research through years Yang et al., 2013) and can be summarized in two approaches: (a) the removal of antigens of diagnostic value in field Brucella infections such as outer membrane and periplasmic proteins (Cloeckaert et al., 2004) or the S-LPS (Godfroid et al., 2000; González et al., 2008) and (b) the genetic engineering approach used here, modifying the Rev1 vaccine by inclusion of foreign (xenogenic) antigens. Rev1 strains lacking protein antigens of diagnostic significance were generated in the past (Cloeckaert et al., 2004) and tested in sheep (Jacques et al., 2007) . The deletion of bp26 gene in the Rev 1 vaccine strain did not alter its biological properties but the diagnostic performance of the BP26 protein was only moderate due either to the low sensitivity of the BP26-ELISA associated test or because Brucella infected sheep did not generate detectable amounts of anti-BP26 antibodies Jacques et al., 2007) .
Other studies have been focused on the inactivation or deletion of genes involved in B. melitensis S-LPS biosynthesis (Godfroid et al., 2000; González et al., 2008) . This strategy may result in excessively attenuated candidates, which limit their protective efficacy (Barrio et al., 2009; González et al., 2008) . Moreover, the rough mutants generated antibodies interfering in some S-LPS tests used for diagnosing B. melitensis infection in small ruminants such as the iELISA, the cELISA and FPA (Moriyón et al., 2004; Barrio et al., 2009) . In addition to our research by gfp stable insertion in the Brucella chromosome, vaccine prototypes using non-integrative plasmids carrying heterologous genes have been constructed (Comerci et al., 1998; Pollevick et al., 1991) lambs. Studies in mice proved that the recombinant GFP given alone lacks immunogenicity, as it has been reported previously (Fric, Marek, Hruskova, Holan, & Forstova, 2008) ; and that the co-administration of Rev1::gfp with recombinant GFP increased the anti-GFP response but not in a persistent way (Figure 4) . By contrast, a further adjuvant-GFP booster induced a high and durable anti-GFP antibody response (Figure 4) . Altogether, mice experiments proved that an exogenous GFP booster was essential for a suitable anti-GFP response after Rev1::gfp vaccination, but also that the endogenous expression of GFP induced during Rev1::gfp replication in vivo could be required also to generate this durable anti-GFP response. This requirement has been reported in experiments using other live-attenuated bacteria as vectors of xenogenic antigens (Kotton & Hohmann, 2004) . Finally, in contrast to that reported in other Gram negative bacteria (Gupta & Chaphalkar, 2015) , the B. melitensis Rev1 S-LPS does not act as an adjuvant for GFP protein. The availability of a GFP tagged Rev1 strain able to express GFP more efficiently than our Rev1::gfp construct could avoid the need of using recombinant GFP for both co-vaccination and booster, thus reducing the costs of the complex vaccination procedure. As mentioned above, the Rev1pGFP synthetized significantly higher GFP amounts than the Rev1::gfp construct and retained the biological properties of Rev1 (not shown) but, unfortunately, this prototype was unable to retain the non-integrative plasmid. To improve the tagging of Rev1 we are conducting currently different approaches to insert either one mini-Tn7-gfp carrying multiple gfp copies or multiple mini-Tn7 in attTn7 sites generated artificially, which have been tested successfully in other bacteria (Choi, Bourque, Morel, Groleau, & Míguez, 2006; Roos, Werner, & Loessner, 2015) . However, an equilibrium between GFP expression and the maintenance of the vaccine properties should be taken into account to avoid over attenuated constructs resulting in poor protective efficacy. Also, we are currently applying the GFP tagging in alternative vaccine candidates generating less anti S-LPS antibodies than Rev1 and/or lacking antigens of diagnostic significance in virulent Brucella strains. Combination of both approaches could be a valuable tool for the eradication of brucellosis in contexts in which vaccination is required. 
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